PT Pyridam Farma TbkISX:PYFA -4.40%68 Piotroski F-Score is 2 as of Jul. 01, 2026, which is 60% below its 10-year median of 5.00. GuruFocus rates ISX:PYFA with a GF Score™ of 68/100 and a GF Value™ of Rp212.75 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 978 Drug Manufacturers companies, PT Pyridam Farma Tbk ranks worse than 91.31% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Pyridam Farma Tbk has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for PT Pyridam Farma Tbk's Piotroski F-Score or its related term are showing as below:
ISX:PYFA'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 9
Current: 2
During the past 13 years, the highest Piotroski F-Score of PT Pyridam Farma Tbk was 9. The lowest was 2. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
PT Pyridam Farma Tbk Piotroski F-Score Related Terms
PT Pyridam Farma Tbk Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was -122608.651 + -152614.251 + -13854.077 + -80875.904 = Rp-369,953 Mil. Cash Flow from Operations was -155839.663 + -81075.901 + -28539.035 + -192320.409 = Rp-457,775 Mil. Revenue was 699947.039 + 674838.042 + 700180.609 + 766533.599 = Rp2,841,499 Mil. Gross Profit was 114385.993 + 123229.44 + 165285.198 + 192761.574 = Rp595,662 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(5962669.485 + 6852812.915 + 6919407.42 + 6771130.415 + 7066339.232) / 5 = Rp6714471.8934 Mil. Total Assets at the begining of this year (Mar25) was Rp5,962,669 Mil. Long-Term Debt & Capital Lease Obligation was Rp4,112,423 Mil. Total Current Assets was Rp1,511,757 Mil. Total Current Liabilities was Rp1,765,948 Mil.
Net Income was -48515.791 + -122613.777 + -116009.996 + -90593.121 = Rp-377,733 Mil.
Revenue was 255684.997 + 754509.814 + 758981.42 + 685456.361 = Rp2,454,633 Mil. Gross Profit was 87776.011 + 148919.364 + 240717.705 + 180243.881 = Rp657,657 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1912192.449 + 6162584 + 5892993 + 5811090.529 + 5962669.485) / 5 = Rp5148305.8926 Mil. Total Assets at the begining of last year (Mar24) was Rp1,912,192 Mil. Long-Term Debt & Capital Lease Obligation was Rp3,317,567 Mil. Total Current Assets was Rp1,581,171 Mil. Total Current Liabilities was Rp1,275,170 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
PT Pyridam Farma Tbk's current Net Income (TTM) was -369,953.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
PT Pyridam Farma Tbk's current Cash Flow from Operations (TTM) was -457,775.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
PT Pyridam Farma Tbk's return on assets of this year was -0.06204484. PT Pyridam Farma Tbk's return on assets of last year was -0.19753905.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
PT Pyridam Farma Tbk's gearing of this year was 0.61247157. PT Pyridam Farma Tbk's gearing of last year was 0.64439978.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
PT Pyridam Farma Tbk's current ratio of this year was 0.85605992. PT Pyridam Farma Tbk's current ratio of last year was 1.23996826.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
PT Pyridam Farma Tbk's number of shares in issue this year was 11236.694. PT Pyridam Farma Tbk's number of shares in issue last year was 11111.831.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
PT Pyridam Farma Tbk's gross margin of this year was 0.20962955. PT Pyridam Farma Tbk's gross margin of last year was 0.26792481.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
PT Pyridam Farma Tbk's asset turnover of this year was 0.47654818. PT Pyridam Farma Tbk's asset turnover of last year was 1.28367445.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Pyridam Farma Tbk has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
PT Pyridam Farma Tbk (ISX:PYFA) has a Piotroski F-Score of 2 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Pyridam Farma Tbk and its competitors. This is 60% below median its historical median of 5.00. Over the past decade, PT Pyridam Farma Tbk's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #893 out of 978 companies in the Drug Manufacturers industry, placing it in the top 91.3%.
Is PT Pyridam Farma Tbk's Piotroski F-Score too high?
PT Pyridam Farma Tbk's current Piotroski F-Score of 2 is 60% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. PT Pyridam Farma Tbk's value of 2 is 60% below this industry median. Based on the distribution chart, PT Pyridam Farma Tbk ranks #893 out of 978 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #893 out of 978 companies for Piotroski F-Score. This places PT Pyridam Farma Tbk in the lower half of its industry. The industry median Piotroski F-Score is 5.00. PT Pyridam Farma Tbk's value of 2 is 60% below this benchmark. Historically, PT Pyridam Farma Tbk's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, PT Pyridam Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Pyridam Farma Tbk's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Pyridam Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Pyridam Farma Tbk's current Piotroski F-Score is 2, which is 60% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp212.75, compared to a current price of Rp174.00 — trading 18.2% below its estimated fair value. The current Piotroski F-Score is 2, which is 60% below median its 10-year median of 5.00 and 60% below the Drug Manufacturers industry median of 5.00. PT Pyridam Farma Tbk's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Piotroski F-Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp174.00 is trading 18.2% below its estimated GF Value™ of Rp212.75.
GuruFocus considers PT Pyridam Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PYFA:
Piotroski F-Score: 2 (60% below median its 10-year median of 5.00)
GF Value™: Rp212.75 vs. price of Rp174.00 (18.2% below fair value)
Industry Position: 60% below the Drug Manufacturers median (#893 of 978)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
68GF Score
Get the complete analysis for ISX:PYFA
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
